New drug combo aims to shrink Hard-to-Treat tumors

NCT ID NCT06848699

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 21, 2026 · Updated 25 times

Summary

This study is for people with advanced or metastatic solid tumors, including non-small cell lung cancer, who have not responded to other treatments. It tests a combination of two drugs: HLX43 (an antibody-drug conjugate targeting PD-L1) and serplulimab (an immunotherapy). The goal is to find the safest dose and see if the combination can shrink tumors. About 105 adults aged 18 to 75 will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hunan Provincial Cancer Hospital
RECRUITING

Hunan, Changsha, 410031, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Second Affiliated Hospital of Army Medical University, PLA
RECRUITING

Chongqing, 400000, China

Contact
Shandong Cancer Hospital
RECRUITING

Jinan, Shangdong, China

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER SOLID TUMOR CANCER